Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunoadsorption Versus Immunoglobulins for CIDP
NCT04881682Phase 2Recruiting
- Sponsor
- Ulm University
- Start
- May 2023
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 2, randomised trial in chronic inflammatory demyelinating polyneuropathy (CIDP) (2 arms), sponsored by Ulm University. Primary endpoints: Chronic Inflammatory Demyelinating Polyneuropathy Score at 15 weeks, Inflammatory Neuropathy Cause and Treatment Disability Score at 15 weeks and 2 more. Started May 2023; status: recruiting.
02
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT04881682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04881682.